Skip to main content

Imaging mass spectrometry of the visual system: Advancing the molecular understanding of retina degenerations.


AUTHORS

Bowrey| Anderson| Pallitto| Gutierrez| Fan| Crouch| Schey| Ablonczy HE| DM| P| DB| J| RK| KL| Z , . Proteomics. Clinical applications. 2015 11 20; ().

ABSTRACT

Visual sensation is fundamental for quality of life, and loss of vision to retinal degeneration is a debilitating condition. The eye is the only part of the central nervous system that can be non-invasively observed with optical imaging. In the clinics, various spectroscopic methods provide high spatial resolution images of the fundus and the developing degenerative lesions. However, the currently utilized tools are not specific enough to establish the molecular underpinnings of retinal diseases. In contrast, imaging mass spectrometry (IMS) is a powerful tool to identify molecularly specific disease indicators and classification markers. This technique is particularly well suited to the eye, where molecular information can be correlated with clinical data collected via non-invasive diagnostic imaging modalities. Recent studies during the last few recent years have uncovered a plethora of new spatially-defined molecular information on several vision-threatening diseases, including age-related macular degeneration (AMD), Stargardt disease, glaucoma, cataract, as well as lipid disorders. Even though mass spectrometry inside the eye cannot be performed non-invasively, by linking diagnostic and molecular information, these studies are the first step toward the development of smart ophthalmic diagnostic and surgical tools. Here we provide an overview of current approaches applying IMS technology to ocular pathology. This article is protected by copyright. All rights reserved.



Leave a Response

You must be logged in to post a comment